Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognized in the beginning of 2020 and is responsible for the present COVID-19 pandemic. Continued research in elucidating the dynamics of the SARS-CoV-2 life cycle is essential to facilitate the design and development of novel diagnostics and antiviral therapies. In a recent investigation highlighted below, results from high throughput sequencing studies shed light on novel aspects of the SARS-CoV-2 genome, transcriptome, and epitranscriptome and their impact on viral life cycle management.
The SARS-CoV-2 Genome
SARS-CoV-2 consists of a positive-sense single-stranded RNA genome, spanning 29,903 nucleotides in length, and 4 different types of structural proteins: N, S, E, and M. The N, or nucleocapsid, protein encapsidates the genome, while the S (spike), E (envelope), and M (membrane) proteins comprise the surrounding lipid bilayer envelope. Of particular appeal is the S protein, which enables viral infection via ACE-2 receptor recognition and membrane fusion, making this structural protein and its host cell receptor ideal targets for therapeutic intervention. The genome of positive-strand RNA viruses like CoVs can act as mRNA and be directly translated into protein within their host cells. Negative-strand RNA intermediates are also produced by CoVs that serve as templates for: positive-strand synthesis of genomic RNA, which is then packaged by the structural proteins to assemble virion offspring; and subgenomic RNA transcripts (discussed in the next section).






